Immunization of disease-free melanoma patients with different HLA-A2 peptides.

Cliniques Universitaires Saint-Luc0 个研究点目标入组 28 人开始时间: 2006年2月22日最近更新: 2023年10月23日

适应症

试验速览

暂无简介。

•1. histologically proven cutaneous melanoma
•2. Patient's melanoma must be in one of the following AJCC stages: only primary tumor (T3b-T4N0M0), regional lymph node metastatsis and/or in-transit metastasis, no distant metastasis (any T N1-N3M0) that has been removed; any distant metastatsis that has been removed (M1).
•3. HLA-A2 positive.
•4. Patients with previous regional metastatic disease must have one of their resected lesions analyzed by RT-PCR to determine expression of genes MAGE-1, MAGE-3, MAGE-4, MAGE-10, MAGE-C2, NA17, Tyrosinase or NY-ESO-1. However, expression of these genes by the tumor is not required.
•5. Absence of detectable melanoma lesions.
•6. WHO/ECOG performance status of 1 or less
•7. Laboratory results with certain values.
•8. Age more than 18 years
•9. Able to give written informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Clinically significant heart disease (NYHA Class III or IV)
•2. Other serious illnesses, e.g. serious infections requiring antibiotics, bleeding disorders, a second active malignancy, except basal cell carcinoma or in situ carcinoma of the uterine cervix.
•3. Active immunodeficiency disease or autoimmune disease.
•4. Prositive serology for HIV or HCV. Serum hepatitis B antigen (HbS Ag) must be negative.
•5. More than on line of previous chemotherapy, or immunotherapy for the melanoma.
•6. Previous vaccination with one of the antigen present in the vaccine.
•7. Treatment with steroids or major immunosuppressive drugs within 4 weeks before study entry. Topical or inhalated steroids are permitted.
•8. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.
•9. Pregnancy or lactation.
•10. Women of childbearing potential not using a medically acceptable means of contraception.
•11. Psychiatric or addictive disorders that may compromise the ability to give informed consent.
•12. Lack of availability of the patient for immunological and clinical follow-up assessment.

发起方